Article
Host-based Th2 cell therapy for prolongation of cardiac allograft viability.
PloS one - 29 Apr 2011
Amarnath Shoba, Chen Hao, Foley Jason E, Costanzo Carliann M, Sennesh Joel D, Solomon Michael A, Fowler Daniel H
Abstract excerpt
Donor T cell transfusion, which is a long-standing approach to prevent allograft rejection, operates indirectly by alteration of host T cell immunity. We therefore hypothesized that adoptive transfer of immune regulatory host Th2 cells would represent a novel intervention to enhance cardiac allograft survival. Using a well-described rat cardiac transplant model, we first developed a method for ex vivo manufacture...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
